Rhythm Pharmaceuticals saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, rising from 79 to 84.
This unique rating identifies market leadership by using a 1 (worst) to 99 (best) score that shows how a stock's price action over the trailing 52 weeks matches up against the rest of the market.
Over 100 years of market history reveals that the top-performing stocks typically have an RS Rating of at least 80 as they launch their biggest climbs.
Risk Management In The Stock Market: How Much Money To Invest Now
While now is not an ideal time to invest, see if the stock manages to form a consolidation and break out.
The company showed 0% earnings growth in its most recent report. Revenue increased 73%.
Rhythm Pharmaceuticals holds the No. 108 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Krystal Biotech and Catalyst Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Technical Action?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
